Odyssey Therapeutics (ODTX) Stock Price, News & Analysis

Company Overview

Key Stats

• Today's Range: $17.45 to $18.55
• 50-Day Range: N/A
• 52-Week Range: $15.35 to $20.30
• Volume: 252,772 shs
• Average Volume: 365,517 shs
• Market Capitalization: $867.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.00
• Consensus Rating: Moderate Buy

Odyssey Therapeutics Stock Analysis - MarketRank™

Odyssey Therapeutics scored higher than 91% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Odyssey Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Odyssey Therapeutics has a consensus price target of $32.00, representing about 77.2% upside from its current price of $18.06.

Amount of Analyst Coverage

Odyssey Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.80% of the float of Odyssey Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Odyssey Therapeutics has a short interest ratio ("days to cover") of 4.75.

Change versus previous month

Short interest in Odyssey Therapeutics has recently increased by 161.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Odyssey Therapeutics does not currently pay a dividend.

Dividend Growth

Odyssey Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.09

News Sentiment

Odyssey Therapeutics has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Odyssey Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for ODTX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

7 insiders have purchased shares of Odyssey Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $75,287,946.00 in company stock, which represents 8.6793% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Odyssey Therapeutics insiders have bought 234,981.10% more of their company's stock than they have sold. Specifically, they have bought $75,319,986.00 in company stock and sold $32,040.00 in company stock.

Percentage Held by Institutions

Odyssey Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 6/17/2026
• Today: 6/27/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ODTX
• CIK: 1882782
• Web: N/A
• Phone: N/A
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Odyssey Therapeutics: $32.00
• High Price Target: $40.00
• Low Price Target: $26.00
• Potential Upside/Downside: +77.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.06 million
• Price / Sales: 819.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 48,031,000
• Free Float: N/A
• Market Cap: $867.44 million
• Optionable: N/A
• Beta: N/A